MUMBAI, India, July 5 -- Intellectual Property India has published a patent application (202517057316 A) filed by Neurimmune Ag, Schlieren, Switzerland, on June 14, for 'pharmaceutical compositions for treating or preventing transthyretin-mediated amyloidosis.'
Inventor(s) include Michalon, Aubin; and Salzmann, Michael.
The application for the patent was published on July 4, under issue no. 27/2025.
According to the abstract released by the Intellectual Property India: "Transthyretin (TTR) is a soluble protein involved in thyroxin and retinol transport in the body. Under specific conditions the TTR protein adopts misfolded, misassembled and/or aggregated TTR conformations and becomes toxic, which can lead to transthyretin-mediated amyloi...